Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Virginia Davenport"'
Autor:
Keith McCarthy, Mark A. Lones, Catherine Patte, Rodney R. Miles, Andrew Wotherspoon, Mitchell S. Cairo, Mary Gerrard, Marie José Terrier-Lacombe, Richard Sposto, Sherrie L. Perkins, Martine Raphael, Anne Auperin, Virginia Davenport
Publikováno v:
Pediatric Blood & Cancer. 51:369-374
Background Diffuse large B-cell lymphoma (DLBCL) makes up 10–20% of pediatric non-Hodgkin lymphoma, and these patients have a significantly better prognosis than adults with DLBCL. The difference in prognosis may be related to clinical, phenotypic,
Autor:
Langdon L. Miller, Virginia Davenport, Mitchell S. Cairo, Mary Ann Bonilla, O. Militano, Mark Krailo, Gregory H. Reaman, Carmella van de Ven, Janet Ayello, Anne L. Angiolillo
Publikováno v:
Clinical Cancer Research. 11:2644-2650
Purpose: Ifosfamide, carboplatin, and etoposide (ICE) are associated with grade III/IV dose-limiting thrombocytopenia. The Children's Oncology Group conducted a phase I dose escalation, pharmacokinetic, and biological study of recombinant human throm
Autor:
Ying-Kuen Cheung, Gregory H. Reaman, Barry Anderson, Virginia Davenport, Mark Krailo, Anne L. Angiolillo, Patrick van Winkle, Mitchell S. Cairo
Publikováno v:
Pediatric Blood & Cancer. 44:338-347
Background The prognosis for children with recurrent/refractory sarcomas is poor. We determined the overall response rate (ORR) and overall survival (OS) of children with recurrent/refractory sarcomas who were given ifosfamide, carboplatin, and etopo
Autor:
Stacy L. Berg, Rita Secola, Gregory H. Reaman, Virginia Davenport, Joseph Laver, Carmella van de Ven, Stanton Goldman, Mitchell S. Cairo, O. Bessmertny, Susan G. Kreissman, Violet Shen
Publikováno v:
British Journal of Haematology. 128:49-58
Thrombocytopenia remains the major dose-limiting toxicity of myelosuppressive chemotherapy in children with solid tumours. Recombinant human interleukin-11 (rhIL-11) has been approved by the Food and Drug Administration as treatment for adults with s
Autor:
C. van de Ven, Virginia Davenport, Mitchell S. Cairo, M.B. Bradley, J.-W. Cai, R.M. Hughes, F. Bracho, E. Areman
Publikováno v:
Cytotherapy. 5:349-361
Background Cord blood (CB) has been used as an alternative source of transplantable allogeneic stem cells for a variety of malignant and non-malignant diseases. However, we have demonstrated delayed recovery of T- and B-cell function, and T-cell subs
Publikováno v:
Leukemialymphoma. 48(1)
Thrombocytopenia occurs at various grades of severity in patients with malignancies undergoing myelosuppressive chemotherapy. In most instances, this is the major dose-limiting hematologic toxicity, especially in the treatment of potentially curable
Autor:
John H. Kersey, Virginia Davenport, Prakash Satwani, Jean E. Sanders, Fevzi Ozkaynak, Mitchell S. Cairo, Michael E. Trigg, Harland N. Sather, Nyla A. Heerema, Kirk R. Schultz
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 13(2)
The prognosis for childhood acute lymphoblastic leukemia (ALL) has improved dramatically over the past quarter of a century. Despite improvements in the treatment of childhood ALL, relapse still occurs in 20%-30% of patients. Although many of these r
Publikováno v:
Clinical advances in hematologyoncology : HO. 1(5)
Paraffin-embedded diagnostic biopsy materials from a large cohort of pediatric and adolescent patients with mature B-cell non-Hodgkin's lymphoma (NHL) treated on the Children's Cancer Group arm of an international cooperative trial were studied to de
Publikováno v:
Pediatric bloodcancer. 45(6)
Pediatric non-Hodgkin lymphoma (NHL) is a common and fascinating group of diseases with distinctive underlying genetic events that characterize the major histologic subtypes: diffuse large B-cell lymphoma, Burkitt lymphoma, anaplastic large cell lymp
Publikováno v:
Cancer treatment reviews. 29(2)
The prognosis of advanced B-large cell lymphoma (B-LCL) in children and adolescents has improved dramatically over the past 25 years (30-40% to 80-90% 5-year event-free survival (EFS)). Using strategies of treatment allocation based upon risk of dise